Key result
Valve-in-valve transcatheter aortic valve implantation resulted in similar rates of 30-day mortality and in-hospital stroke compared to redo surgical aortic valve replacement.
Why the study?
Real-world outcomes comparing valve-in-valve TAVI with redo surgical aortic valve replacement in patients with degenerated biological aortic valve prostheses required investigation.
Does valve-in-valve transcatheter aortic valve implantation reduce the composite of 30-day all-cause mortality and in-hospital postoperative stroke compared to redo surgical aortic valve replacement in patients with degenerated biological aortic valve prostheses?
Cohort (n=653)
Yes
Does valve-in-valve transcatheter aortic valve implantation reduce the composite of 30-day all-cause mortality and in-hospital postoperative stroke compared to redo surgical aortic valve replacement in patients with degenerated biological aortic valve prostheses?
Answers are grounded in this paper and cite their sources.
In patients with degenerated biological aortic valve prostheses, ViV-TAVI and redo-SAVR demonstrated similar rates of mortality and morbidity, suggesting ViV-TAVI is a viable alternative.
OBJECTIVE: We sought to investigate real-world outcomes of patients with degenerated biological aortic valve prostheses who had undergone valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) or reoperative surgical aortic valve replacement (redo-SAVR) in the Netherlands. METHODS: Patients who had undergone ViV-TAVI or redo-SAVR for a degenerated biological aortic valve prosthesis in the Netherlands between January 2014 and December 2018 were eligible for this retrospective study. Patients with a prior homograft, active endocarditis or mechanical aortic valve prosthesis were excluded. Patients were matched using the propensity score. The primary endpoint was a composite of 30-day all-cause mortality and in-hospital postoperative stroke. Secondary endpoints were all-cause mortality at different time points, in-hospital postoperative stroke, pacemaker implantation and redo procedures within one year. Baseline characteristics and outcome data were collected from the Netherlands Heart Registration. RESULTS: From 16 cardiac centres, 653 patients were included in the study (374 ViV-TAVI and 279 redo-SAVR). European System for Cardiac Operative Risk Evaluation I (EuroSCORE I) was higher in ViV-TAVI patients (19.4, interquartile range (IQR) 13.3-27.9 vs 13.8, IQR 8.3-21.9, p < 0.01). After propensity score matching, 165 patients were matched with acceptable covariate balance. In the matched cohorts, the primary endpoint was not significantly different for ViV-TAVI and redo-SAVR patients (odds ratio 1.30, 95% confidence interval 0.57-3.02). Procedural, 30-day and 1‑year all-cause mortality rates, incidence of in-hospital postoperative stroke, pacemaker implantation and redo procedures within one year were also similar between cohorts. CONCLUSION: Patients with degenerated aortic bioprostheses treated with ViV-TAVI or redo-SAVR have similar mortality and morbidity.
No takes yet. Share an insight, caveat, or question.
Steenbergen et al. (2021) conducted a cohort in Degenerated biological aortic valve prosthesis (n=653). Valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) vs. Reoperative surgical aortic valve replacement (redo-SAVR) was evaluated on Composite of 30-day all-cause mortality and in-hospital postoperative stroke (OR 1.30, 95% CI 0.57-3.02, p=0.53). Valve-in-valve transcatheter aortic valve implantation resulted in similar rates of 30-day mortality and in-hospital stroke compared to redo surgical aortic valve replacement.
Synapse has enriched 10 related papers. Consider them for comparative context: